Sheri Wilcox

Sheri Wilcox, Vice President of Scientific Engagement at Nautilus Biotechnology, has spent more than two decades at the forefront of the proteomics revolution to transform biomedicine. At Nautilus, she led the development of short-epitope binding reagents and bioinformatics, both of which enable the Nautilus platform to uncover novel scientific insights about the proteome, prior to creating her current team as part of the company’s commercial platform launch. Sheri’s track record also includes positions at SomaLogic, where she was instrumental in the building of its proteomics platform and in bolstering its library of aptamers to 7,000 targets, and Pharmacia prior to its merger with Pfizer. Sheri holds a Ph.D. from The Scripps Research Institute, and a B.S. from Vanderbilt University.